Dr. Jaslow is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
900 Centennial Blvd
Bldg 1
Voorhees, NJ 08043Phone+1 856-632-2667Fax+1 856-735-6478
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 1999 - 2002
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1996 - 1999- Icahn School of Medicine at Mount SinaiClass of 1996
Certifications & Licensure
NJ State Medical License 2017 - 2025
PA State Medical License 2002 - 2024
DE State Medical License 2017 - 2023
NY State Medical License 1997 - 2002- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Patient-Centered Specialty Practice Recognition Program National Committee for Quality Assurance, 2014-2017
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2011-2013
Clinical Trials
- Tumor Suppressor Status as a Predictor of Chemotherapy Response in Triple Negative Breast Cancer Start of enrollment: 2011 Dec 01
- Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax Start of enrollment: 2013 May 21
- Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer Start of enrollment: 2013 Apr 25
- Join now to see all
Publications & Presentations
PubMed
- 97 citationsProspective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancerZhaomei Mu, Chun Wang, Zhong Ye, Laura Austin, Jesse Civan
Breast Cancer Research and Treatment. 2015-11-16 - 27 citationsPrognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors.Chun Wang, Zhaomei Mu, Zhong Ye, Zhenchao Zhang, Maysa M. Abu-Khalaf
Breast Cancer Research and Treatment. 2020-05-04 - 375 citationsNeratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3...Miguel Martin, Frankie A. Holmes, Bent Ejlertsen, Suzette Delaloge, Beverly Moy
The Lancet. Oncology. 2017-12-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
